May 16 |
Expert Ratings For Caribou Biosciences
|
May 9 |
Caribou Biosciences, Inc. (NASDAQ:CRBU) Analysts Are Cutting Their Estimates: Here's What You Need To Know
|
May 7 |
Caribou Bioscience GAAP EPS of -$0.46 misses by $0.05, revenue of $2.43M beats by $0.01M
|
May 7 |
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
|
May 7 |
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 1 |
Caribou Biosciences to Participate in Upcoming Investor Conferences
|
Apr 24 |
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
Apr 18 |
Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
|
Apr 15 |
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
|
Apr 4 |
Caribou Biosciences received IND clearance from FDA for its lupus treatment
|